Terumo Neuro has unveiled new, real-world US physician preference data for the Sofia 88 neurovascular support catheter at the 2025 Society of NeuroInterventional Surgery (SNIS) annual meeting (14–18 July, Nashville, USA). The data—now presented publicly for the first time—demonstrate “strong performance” compared to other super-bore catheters in key performance metrics like trackability, atraumatic design and overall physician-rated experience, according to the company.
Collected from 105 procedures across 37 US centres and 41 physicians, the preference test revealed that 95% of physicians reported that the Sofia 88 catheter reliably reached the target location—even in anatomically challenging cases, with 59% of procedures in internal carotid artery (ICA)-T or beyond. Also, 86% of physicians rated the Sofia 88 catheter as ‘better’ or ‘much better’ than alternatives overall. Terumo Neuro further relays that physician data revealed that the Sofia 88 catheter outperformed the Zoom 88 catheter (Imperative Care) in 94% of cases and the HiPoint 88 catheter (Route 92 Medical) in 79%.
“These real-world results further validate the Sofia 88 catheter’s position as a leading super-bore support catheter,” said Carsten Schroeder, president and chief executive officer (CEO) of Terumo Neuro. “This new dataset reinforces what we’ve heard consistently from physicians: the Sofia 88 catheter delivers reliable performance where it matters most. We are proud to see the catheter outperform other large-bore devices in real-world settings—and even more proud that this innovation was shaped through close physician partnership. It reflects our longstanding commitment to delivering meaningful neurovascular advancements rooted in evidence, experience, and collaboration.”
The Sofia 88 neurovascular support catheter was commercially launched in the USA on 13 May as the latest addition to Terumo Neuro’s global stroke portfolio. Engineered for reliable trackability, proximal stability, and vessel-friendly flexibility, the Sofia 88 catheter is designed to optimise physician control and integration into a variety of aspiration and combination strategies, the company notes. Terumo Neuro also made the Sofia 88 catheter commercially available in the Europe, the Middle East and Africa (EMEA) region last month.
The physician preference data unveiled at SNIS 2025 build on results from the SOFAST registry, which demonstrated the safety and efficacy of the Sofia Flow Plus 6Fr catheter as a frontline aspiration device.
